UK Markets closed

Respiratory Syncytial Virus - Epidemiology Forecast to 2030

·2-min read

Summary Respiratory syncytial virus (RSV) is a common respiratory infection that most children will be infected with by the time they are two years old. In healthy individuals, RSV usually self-resolves within a week or two without need for significant therapeutic intervention.

New York, Sept. 06, 2021 (GLOBE NEWSWIRE) -- announces the release of the report "Respiratory Syncytial Virus - Epidemiology Forecast to 2030" -

In preterm and very young infants, the elderly, or those with otherwise compromised immune systems, however, RSV can cause severe illness or death.

Epidemiologists provide a well-rounded, evidence-based analysis and forecast for the prophylactic populations for RSV in this report.This analysis covered all at-risk groups that are recommended for RSV prophylactic treatment.

Several of the segmentations are further segmented by age, thereby providing a granular visualization of the RSV prophylactic and hospitalized market in the 8MM.

This report provides an overview of the risk factors, and global and historical trends for the RSV prophylactic population in the 8MM. It also includes a 10-year epidemiology forecast for the pediatric and adult populations that are most at risk for severe RSV infection and are therefore eligible to receive prophylactic treatment (prophylactic population).

- The Respiratory Syncytial Virus (RSV) Epidemiology Report provides an overview of the global trends in risk factors for RSV in the seven major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and Australia).
- The report includes a 10-year epidemiological forecast for the pediatric and adult populations that are at most risk for severe RSV infection and are therefore eligible for prophylactic treatment. This prophylactic population consists of: children born before 37 weeks of gestation (preterm population); preterm births with neonatal chronic lung disease (CLD); live births with hemodynamically significant congenital heart disease; boys 0-2 years old with Duchenne muscular dystrophy (DMD); children 0-2 years old with spinal muscular atrophy (SMA); pregnant women in their third trimester; and adults ? 55 years of age living in nursing homes or other long-term care institutions.
- The RSV epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to Buy
The RSV Epidemiology series will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global RSV market.
- Quantify patient populations in the global RSV market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for RSV therapeutics in each of the markets
- Understand magnitude of RSV population by prophylactic markets
Read the full report:

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.


CONTACT: Clare: US: (339)-368-6001 Intl: +1 339-368-6001

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting